A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term protection against West Nile Virus disease, the researchers said.
The findings, published in Cell Host & Microbe, may represent a breakthrough strategy for treating West Nile Virus after virus invasion of the brain and the central nervous system, noted senior author Priti Kumar, M.D., associate professor of infectious disease at Yale School of Medicine.
There are no approved vaccines or effective therapies for West Nile Virus disease, a mosquito-borne condition. While many infected individuals have no symptoms, others — particularly the very young and older adults — can develop severe neurological problems and even die from the disease. The sporadic nature of the disease makes it exceedingly difficult for testing and implementing vaccines, said Kumar.
To investigate a possible new therapy to treat West Nile Virus disease, Kumar and her colleagues focused on a small “interfering” RNA molecule developed in her lab. The RNA acts against multiple mosquito-borne flaviviruses. To direct the RNA to infected cells, they packaged it in a peptide derived from the rabies virus, which is able to enter nerve cells. The final step was to the deliver the therapy through the nose where it could bypass natural barriers protecting the brain.
With this novel approach, the researchers found that the therapy reduced the virus in the brain, preventing harm to nerve cells. The treated mice had a 90% survival rate a few days after infection compared to mice treated with placebo. Significantly, noted the researchers, in the surviving mice, the immune system cleared the virus throughout the body, and also enabled long-term protection against future exposure.
The researchers concluded that the treatment offers both a promising late-stage therapy and lifelong immunity. It “prevents pathology in the brain and gives the mice a chance to develop a robust immune response,” said Kumar.
While the anatomy of the murine nose differs from that of humans, the researchers plan to study the therapy further with the hope it will be broadly applicable. “In translation, it should be an effective strategy for people,” she said.
If that is the case, the intranasal RNA therapy could theoretically be developed for treatment of other mosquito-borne diseases, such as St. Louis encephalitis, Japanese encephalitis, and perhaps Zika, the researchers noted.
The Latest on: RNA therapy
via Google News
The Latest on: RNA therapy
Top HIV cure research team refutes major recent results on how to identify HIV persistence
on April 18, 2018 at 11:02 am
Microscopic images showing levels of CD32 (green) and HIV-RNA (red) in lymph node tissue from an HIV-infected ... within the immune system of patients undergoing antiretroviral therapy (ART), as proposed by a recent landmark study. Instead, they report ... […]
Researchers develop a novel RNA-based therapy to target West Nile Virus
on April 18, 2018 at 6:21 am
A Yale-led research team developed a new RNA therapy, delivered through the nose, to treat mice infected with West Nile Virus. The innovative approach reduced the virus in the brain, allowing the immune system to destroy the virus and develop long-term ... […]
Genetic Material Considered Junk Could Hold Key To Cancer Drug Response
on April 18, 2018 at 3:04 am
Sequencing a type of genetic material in cancer tumors called messenger RNA has transformed personalized cancer therapy and revealed biomarkers for early detection. Advances in this field have transformed scientists' understanding of the differences ... […]
Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
on April 17, 2018 at 9:48 am
Dr. Frank Bennett, Ionis' senior vice president of research and franchise leader for the neurological programs, will provide a scientific overview on antisense therapy and Dr. Morie ... INC. Ionis is the leading company in RNA-targeted drug discovery ... […]
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
on April 11, 2018 at 2:29 pm
Through its expert team and dominant intellectual property in RNA delivery, Genevant plans to develop products ... It is the first and only LNP platform to enable an approved therapy, and has enabled a second NDA filing through its licensed use by Alnylam ... […]
Following hype, some skepticism about microRNA therapy for cardiovascular diseases
on April 9, 2018 at 7:45 am
Our expert however hopes that a micro RNA biomarker for a specific cardiac event will only be a "question of time" Cardiovascular diseases are still the number one cause of death globally. Some labs and pharmaceutical companies are looking at microRNAs ... […]
Novartis Bets $8.7B on AveXis’s Gene Therapy for Spine Disease
on April 9, 2018 at 5:06 am
The drug, an RNA-based therapy administered a few times a year, for life, through a spinal infusion, was a medical breakthrough. It may slow the progression of multiple types of SMA. Yet nusinersen, which generated $884 million worldwide for Biogen in ... […]
Novartis buys AveXis in $8.7 billion gene therapy bet
on April 9, 2018 at 4:16 am
Novartis's second bet on gene therapy in four months will fuel speculation of mergers ... There are existing treatments for SMA - Biogen's and Ionis's RNA-splicing Spinraza, approved in 2016, generated $363 million in the fourth quarter of 2017 - as ... […]
Novartis bets big on gene therapy with $8.7 billion AveXis deal
on April 9, 2018 at 12:28 am
Novartis’s second bet on gene therapy in four months will fuel speculation of mergers ... There are existing treatments for SMA - Biogen’s and Ionis’s RNA-splicing Spinraza, approved in 2016, generated $363 million in the fourth quarter of 2017 ... […]
via Bing News